KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Retained Earnings: 2017-2025

Historic Retained Earnings for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to -$570.1 million.

  • Amneal Pharmaceuticals' Retained Earnings rose 1.02% to -$570.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$570.1 million, marking a year-over-year increase of 1.02%. This contributed to the annual value of -$607.1 million for FY2024, which is 23.85% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Retained Earnings stood at -$570.1 million for Q3 2025, which was up 0.41% from -$572.5 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Retained Earnings high stood at -$265.6 million for Q2 2021, and its period low was -$607.1 million during Q4 2024.
  • For the 3-year period, Amneal Pharmaceuticals' Retained Earnings averaged around -$524.9 million, with its median value being -$572.5 million (2025).
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Retained Earnings grew by 4.92% in 2021, and later crashed by 50.30% in 2022.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Retained Earnings stood at -$276.2 million in 2021, then slumped by 47.06% to -$406.2 million in 2022, then declined by 20.68% to -$490.2 million in 2023, then fell by 23.85% to -$607.1 million in 2024, then climbed by 1.02% to -$570.1 million in 2025.
  • Its Retained Earnings was -$570.1 million in Q3 2025, compared to -$572.5 million in Q2 2025 and -$594.9 million in Q1 2025.